METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Clinical trials for METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New vaccine aims to boost immune system against advanced breast cancer
Disease control Recruiting nowThis study tests a vaccine called STEMVAC in people with hormone receptor-positive, HER2-negative breast cancer that has spread. The vaccine is designed to help the immune system attack cancer cells. Participants will receive STEMVAC along with their usual hormone therapy, a targ…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a PET scan predict which breast cancer patients will respond to treatment?
Knowledge-focused Recruiting nowThis study tests whether a special type of PET scan (FFNP-PET/CT) can predict how well a drug combination (abemaciclib plus hormone therapy) works in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 60 participants with metastatic or locally adva…
Matched conditions: METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC